Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) Sees Significant Increase in Short Interest

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 3,038,967 shares, an increase of 1,004.7% from the April 15th total of 275,084 shares. Approximately 29.1% of the shares of the company are short sold. Based on an average daily trading volume, of 17,378,163 shares, the days-to-cover ratio is currently 0.2 days.

Calidi Biotherapeutics Stock Down 5.7%

CLDI stock opened at $0.20 on Tuesday. The firm has a market cap of $2.16 million, a PE ratio of -0.03 and a beta of 1.38. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 1.59. The firm’s fifty day moving average is $0.32 and its 200 day moving average is $0.90. Calidi Biotherapeutics has a one year low of $0.19 and a one year high of $19.20.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last released its quarterly earnings results on Friday, March 27th. The company reported $0.45 EPS for the quarter.

Institutional Trading of Calidi Biotherapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CLDI. Virtu Financial LLC acquired a new stake in shares of Calidi Biotherapeutics in the fourth quarter valued at about $25,000. Warberg Asset Management LLC purchased a new position in shares of Calidi Biotherapeutics in the third quarter worth about $28,000. Geode Capital Management LLC lifted its stake in shares of Calidi Biotherapeutics by 41.7% in the fourth quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after buying an additional 12,334 shares in the last quarter. Finally, DRW Securities LLC purchased a new position in shares of Calidi Biotherapeutics in the fourth quarter worth about $173,000. Institutional investors and hedge funds own 12.53% of the company’s stock.

Calidi Biotherapeutics Company Profile

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.